Prague Med. Rep. 2013, 114, 162-171
https://doi.org/10.14712/23362936.2014.18
25-hydroxyvitamin D3 Concentration in Serum and Cerebrospinal Fluid of Patients with Remitting-relapse Multiple Sclerosis
References
1. 1984) 25-hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. Klin. Wochenschr. 62(22), 1086–1090.
< , S., Richter, H. P., Antoniadis, G., Homoki, J., Kremmer, N., Hanle, J., Teller, W. M. (https://doi.org/10.1007/BF01711378>
2. 2003) 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci. Lett. 343(2), 139–143.
< , J., Bianco, J. I., McGrath, J. J., Eyles, D. W. (https://doi.org/10.1016/S0304-3940(03)00303-3>
3. 2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179(3), 1634–1647.
< , S., Sims, G. P., Chen, X. X., Gu, Y. Y., Chen, S., Lipsky, P. E. (https://doi.org/10.4049/jimmunol.179.3.1634>
4. 2009) Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132(Pt 5), 1146–1160.
< , J., Ysrraelit, M. C., Gaitán, M. I. (https://doi.org/10.1093/brain/awp033>
5. 2000) Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 48(2), 271–272.
< , A. F., Snowdon, L. R., Vieth, R. (https://doi.org/10.1002/1531-8249(200008)48:2<271::AID-ANA28>3.0.CO;2-O>
6. 2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 29(1), 21–30.
< , D. W., Smith, S., Kinobe, R., Hewison, M., McGrath, J. J. (https://doi.org/10.1016/j.jchemneu.2004.08.006>
7. 1974) Evaluation of molecular size by gel electrophoretic techniques. Hoppe Seylers Z. Physiol. Chem. 355(10), 1281–1290.
< , K. (https://doi.org/10.1515/bchm2.1974.355.2.1281>
8. 1997) 1,25-dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res. Mol. Brain Res. 45(2), 255–267.
< , E., Nataf, S., Berod, A., Darcy, F., Brachet, P. (https://doi.org/10.1016/S0169-328X(96)00260-4>
9. 1998) Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 22(3), 282–294.
< , E., Sindji, L., Montero-Menei, C., Andre, C., Brachet, P., Darcy, F. (https://doi.org/10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7>
10. 2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13(3), 100–105.
< , E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F., Wion, D. (https://doi.org/10.1016/S1043-2760(01)00547-1>
11. 2006) Multiple sclerosis cerebrospinal fluid biomarkers. Dis. Markers 22(4), 187–196.
< , G. (https://doi.org/10.1155/2006/509476>
<PubMed>
12. 2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 22(7), 340–345.
< , P. T., Bertolini, J. (https://doi.org/10.1016/j.tibtech.2004.05.001>
13. 2009) Vitamin D status: measurement, interpretation, and clinical application. Ann. Epidemiol. 19(2), 73–78.
< , M. F. (https://doi.org/10.1016/j.annepidem.2007.12.001>
<PubMed>
14. 2010) Alaska, multiple sclerosis, and the vitamin D hypothesis. J. Neurol. 257(2), 305–306.
< , T., Kampman, M. T. (https://doi.org/10.1007/s00415-009-5360-7>
15. 2009) 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult. Scler. 15(11), 1280–1285.
< , T., Moen, S. M., Gundersen, T. A., Holick, M. F., Fainardi, E., Castellazzi, M., Casetta, I. (https://doi.org/10.1177/1352458509107008>
16. 2010). The role of vitamin D in multiple sclerosis. J. Photochem. Photobiol. B 101(2), 137–141.
< , M. T., Steffensen, L. H. (https://doi.org/10.1016/j.jphotobiol.2010.04.003>
17. 2011) Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult. Scler. 17(12), 1418–1423.
< , S., Smolders, J., Thewissen, M., Peelen, E., Tervaert, J. W., Hupperts, R., Damoiseaux, J. (https://doi.org/10.1177/1352458511412655>
18. 2000) Multiple sclerosis in time and space – geographic clues to cause. J. Neurovirol. 6, S134–S140 (Suppl. 2).
, J. F. (
19. 2011) Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J. Neuroimmunol. 233(1–2), 240–244.
< , A. P., Jaquiéry, E., Jilek, S., Pantaleo, G., Schluep, M., Du Pasquier, R. A. (https://doi.org/10.1016/j.jneuroim.2010.11.008>
20. 2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50(1), 121–127.
< , W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B. Y., Wolinsky, J. S. (https://doi.org/10.1002/ana.1032>
21. 2011) Prevention and treatment of MS: studying the effects of vitamin D. Mult. Scler. 17(12), 1405–1411.
< , K. L., Ascherio, A. (https://doi.org/10.1177/1352458511425366>
<PubMed>
22. 2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1), 60–65.
< , K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., Ascherio, A. (https://doi.org/10.1212/01.WNL.0000101723.79681.38>
23. 2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23), 2832–2838.
< , K. L., Levin, L. I., Hollis, B. W., Howard, N. S., Ascherio, A. (https://doi.org/10.1001/jama.296.23.2832>
24. 1996) 1,25-dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 7(13), 2171–2175.
< , P., Neveu, I., Wion, D., Brachet, P. (https://doi.org/10.1097/00001756-199609020-00023>
25. 1994) 1,25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport 6(1), 124–126.
< , I., Naveilhan, P., Baudet, C., Brachet, P., Metsis, M. (https://doi.org/10.1097/00001756-199412300-00032>
26. 2005) Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 23(4), 309–313.
< , S., Bulut, S., Ilhan, N., Gulkesen, A., Ardicoglu, O., Ozkan, Y. (https://doi.org/10.1007/s00774-005-0604-9>
27. 1985) Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. J. Neurochem. 44(4), 1138–1141.
< , W. M., Sakiyama, R., Coty, W. A. (https://doi.org/10.1111/j.1471-4159.1985.tb08735.x>
28. 2009) Clinical implications of a possible role of vitamin D in multiple sclerosis. J. Neurol. 256(9), 1468–1479.
< , C. (https://doi.org/10.1007/s00415-009-5139-x>
<PubMed>
29. 2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58(6), 840–846.
< , C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O’Connor, P. W., Sandberg-Wollheim, M., Thompson, A. J., Weinshenker, B. G., Wolinsky, J. S. (https://doi.org/10.1002/ana.20703>
30. 2009) Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell. Mol. Neurobiol. 29(2), 203–210.
< , Z., Qin, Y., Liu, S. (https://doi.org/10.1007/s10571-008-9312-z>
31. 2008) Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 194(1–2), 7–17.
< , J., Damoiseaux, J., Menheere, P., Hupperts, R. (https://doi.org/10.1016/j.jneuroim.2007.11.014>
32. 2006) Seasonal fluctuation of multiple sclerosis births in Sardinia. J. Neurol. 253(1), 38–44.
< , S., Pugliatti, M., Sotgiu, M. A., Fois, M. L., Arru, G., Sanna, A., Rosati, G. (https://doi.org/10.1007/s00415-005-0917-6>
33. 2005) Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J. Neurogenet. 19(1), 25–38.
< , L., Ovcaric, M., Curtain, R., Johnson, M. P., Griffiths, L. R., Csurhes, P., Pender, M. P., Lea, R. A. (https://doi.org/10.1080/01677060590949692>
34. 2009) Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 35(2), 117–127.
< , H., Hartung, H. P., Hemmer, B., Teunissen, C., Deisenhammer, F., Giovannoni, G., Zettl, U. K.; BioMS Study Group (https://doi.org/10.1016/j.nbd.2009.04.010>
35. 1991) 1,25-dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res. 28(1), 110–114.
< , D., MacGrogan, D., Neveu, I., Jehan, F., Houlgatte, R., Brachet, P. (https://doi.org/10.1002/jnr.490280111>